|
|
Iranian Journal of Otorhinolaryngology، جلد ۲۷، شماره ۶، صفحات ۴۵۳-۴۵۸
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
Montelukast in Adenoid Hypertrophy: Its Effect on Size and Symptoms |
|
| چکیده انگلیسی مقاله |
Introduction: Adenotonsillar hypertrophy (AH) is considered the most common cause of upper respiratory tract obstruction among children. It results in a spectrum of symptoms from mouth breathing, nasal obstruction, hyponasal speech, snoring, and obstructive sleep apnea (OSA) to growth failure and cardiovascular morbidity. Adenotonsillectomy is a typical strategy for patients with AH, but may lead to serious complications such as bleeding (4–5%) and postoperative respiratory compromise (27%), especially among young children, as well as recurrence of adenoid tissue (10–20%). Thus, non-surgical therapies have attracted considerable attention as an alternative strategy. The inflammatory mechanism proposed for AH has lead to the use of anti-inflammatory drugs to manage this condition. The present study aimed to evaluate the effect of chewable tablets of montelukast, a cysteinyl- leukotriene receptor antagonist, in children with AH. Materials and Methods: Sixty children between the ages of 4–12 years with >75% choanal obstruction on primary nasal endoscopy were recruited in this randomized, placebo-controlled trial and randomly divided into two groups. The study group was treated with montelukast 5 mg daily for 12 weeks while the control group received matching placebo for the same period of time. A questionnaire was completed by each child’s parent/guardian to assess the severity of sleep discomfort, snoring, and mouth breathing before and after the intervention. Results: Adenoid size decreased in 76% of the study group compared with 3% of the placebo group after 12 weeks. A statically significant improvement was observed in the study group compared with the placebo group in terms of sleep discomfort, snoring, and mouth breathing. The symptoms average total score dropped from 7.7 to 3.3 in the study group, while in the placebo group the total score changed from 7.4 to 6.7. Conclusion: Montelukast chewable tablets achieved a significant reduction in adenoid size and improved the related clinical symptoms of AH and can therefore be considered an effective alternative to surgical treatment in children with adenoid hypertrophy. |
|
| کلیدواژه‌های انگلیسی مقاله |
|
|
| نویسندگان مقاله |
فرشید شکوهی | farshid shokouhi
department of otorhinolaryngology, faculty of medicine, mashhad university of medical sciences, mashhad, iran.
سازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)
احمد میمنه جهرمی | ahmad meymaneh jahromi
department of otorhinolaryngology, faculty of medicine, mashhad university of medical sciences, mashhad, iran.
سازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)
محمدرضا مجیدی | mohamad reza majidi
sinus and surgical endoscopic research center, ghaem hospital, faculty of medicine, mashhad university of medical sciences, mashhad, iran.
سازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)
مریم صالحی | maryam salehi
department of community medicine, faculty of medicine, mashhad university of medical sciences, mashhad, iran.
سازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)
|
|
| نشانی اینترنتی |
http://ijorl.mums.ac.ir/article_5484.html |
| فایل مقاله |
اشکال در دسترسی به فایل - ./files/site1/rds_journals/11/article-11-80922.pdf |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
|
| نوع مقاله منتشر شده |
Original |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|